[Home ] [Archive]   [ فارسی ]  
:: Main :: About us :: Current Issue :: Archive :: Search :: Submit :: Contact ::
Main Menu
Home::
Journal Information::
Articles archive::
For Authors::
For Reviewers::
Subscription::
News& Events::
Contact us::
Site Facilities::
::
Search in website

Advanced Search
..
Receive site information
Enter your Email in the following box to receive the site news and information.
..
Indexing
                        
..
:: Volume 12, Issue 1 (Spring 2015) ::
Sci J Iran Blood Transfus Organ 2015, 12(1): 23-13 Back to browse issues page
Investigation of p53 codon 72 polymorphism in patients with acute myeloid leukemia in Iran
M. Nikbakht Dastjerdi
Keywords: Key words : TP53 Genes, Acute Myeloid Leukemia, Polymorphism(Genetic), Iran
Full-Text [PDF 320 kb]   (1993 Downloads)     |   Abstract (HTML)  (6514 Views)
Type of Study: Research | Subject: Hematology and Oncology
Published: 2015/04/7
Full-Text:   (2254 Views)
References :  
  1. Kumar V, Abbas AK, Fausto N, Mitchell RN. Robbins Basic Pathology. 8th ed. Philadelphia: Saunders Elsvier; 2007. p. 174.
  2. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009; 114(5): 937-51.
  3. Weng Y, Lu L, Yuan G, Guo J, Zhang Z, Xie X, et al. P53  codon 72 polymorphism and hematological cancer risk: an update meta-analysis. PLoS One 2012; 7(9): e45820.
  4. Hofseth LJ, Hussain SP, Harris CC. p53: 25 years after its discovery. Trends Pharmacol Sci 2004; 25(4): 177-81.
  5. Wang SP, Wang WL, Chang YL, Wu CT, Chao YC, Kao SH, et al. p53  controls cancer cell invasion by inducing the MDM2-mediated degradation of Slug. Nat Cell Biol 2009; 11(6): 694-704.
  6. Cao Z, Song JH, Park YK, Maeng EJ, Nam SW, Lee JY, et al. The p53 codon 72 polymorphism and susceptibility to colorectal cancer in Korean patients. Neoplasma 2009; 56(2): 114-8.
  7. Santos AM, Sousa H, Portela C, Pereira D, Pinto D, Catarino R, et al. TP53  and P21 polymorphisms: response to cisplatinum/paclitaxel-based chemotherapy in ovarian cancer. Biochem Biophys Res Commun 2006; 340(1): 256-62.
  8. Chang FH, Tzeng DS, Lee TM, Chen TC, Hsu LS, Lung FW. Mutations in the p53 tumor suppressor gene in colorectal cancer in Taiwan. Kaohsiung J Med Sci 2003; 19(4): 151-8.
  9. Zhang J, Zhuo WL, Zheng Y, Zhang YS. Polymorphisms of TP53  codon 72 with prostate carcinoma risk: a meta-analysis. Med Oncol 2009; 27(2): 540-6.
  10. Aoki MN, da Silva do Amaral Herrera AC, Amarante MK, do Val Carneiro JL, Fungaro MH, Watanabe MA. CCR5 and p53 codon 72 gene polymorphisms: implications in breast cancer development. Int J Mol Med 2009; 23(3): 429-35.
  11. Faghani M, Nikbahkt M, Salehi M, Rabbani M, Talebi A, Soleimani B, et al. Study of p53 polymorphism at codon 72 in patients of breast cancer in Isfahan. J Isfahan Med 2007; 25(84): 679-85.
  12. Mahasneh AA, Abdel-Hafiz SS. Polymorphism of p53  gene in Jordanian population and possible assosiations with breast cancer and lung adenocarcinoma. Saudi Med J 2004; 25(11): 1568-73.
  13. Zhou C, Chen H, Wang A. P53 codon 72 polymorphism and lung cancer risk: evidence from 27,958 subjects. Tumour Biol 2013; 34(5): 2961-9.
  14. Suzuki K, Matsui H, Ohtake N, Nakata S, Takei T, Nakazato H, et al. A p53 codon 72 polymorphism associated with prostate cancer development and progression in Japanese. J Biomed Sci 2003; 10(4): 430-5.
  15. Dastjerdi MN. TP53 codon 72 polymorphism and P53  protein expression in colorectal cancer specimen in Isfahan. Acta Med Iran 2011; 49(2): 71-7.   
  16. Nikbahkt Dastjerdi M, Mirmohammad Sadeghi H.
 
TP53 codon 72 heterozygosity may promote microsatellite instability in sporadic colorectal cancer. Yakhteh 2010; 12(1): 25-32 .  
  1. Nikbahkt Dastjerdi M, Salehi M, Mohajeri MR, Morsali F, Mirmohammad Sadeghi H, Esfandiary E. Evidence for an association of TP53  codon 72 polymorphism with sporadic colorectal cancer risk in Isfahan. JRMS 2008; 13(6): 317-23.
  2. Nikbakht Dastjerdi M, Hasanzadeh M, Talebi A, Akbari M. Investigation of p53 codon 72 polymorphism in patients with nonmelanoma skin cancers in Isfahan. J Isfahan Med School 2011; 29(141): 679-84. [Article in Farsi]
  3. Xiong X, Wang M, Wang L, Liu J, Zhao X, Tian Z, et al. Risk of MDM2 SNP309 alone or in combination with the p53  codon 72 polymorphism in acute myeloid leukemia. Leuk Res 2009; 33(11): 1454-8.
  4. Bergamaschi G, Merante S, Orlandi E, Galli A, Bernasconi P, Cazzola M. TP53 codon 72 polymorphism in patients with chronic myeloid leukemia. Haematologica 2004; 89(7): 868-9.
  5. Majid A, Richards T, Dusanjh P, Kennedy DB, Miall F, Gesk S, et al. TP53  codon 72 polymorphism in patients with chronic lymphocytic leukaemia: identification of a subgroup with mutated IGHV genes and poor clinical outcome. Br J Haematol 2011; 153(4): 533-5.
  6. Hamú CS, Oliveira MVP, Silva AMTC, Silva CC, Cruz AD. Codon 72 polymorphism of the TP53  gene in patients suspected to have CML. Rev Bras Hematol Hemoter 2007; 29(4): 346-50. [Article in Portuguese]
  7. Nikbakht Dastjerdi M, Eslami B, Abutorabi R. Association of TP53 gene codon 72 polymorphism with endometriosis risk in Isfahan. Iran J Reprod Med 2013; 11(6): 473-8.
  8. Hildesheim A, Schiffman M, Brinton LA, Fraumeni JF Jr,  Herrero R, Bratti MC, et al. p53  polymorphism and risk of cervical cancer. Nature 1998; 396(6711): 531-2.
  9. Storey A, Thomas M, Kalita A, Harwood C, Gardiol D, Mantovani F, et al. Role of a p53  polymorphism in the development of human papillomavirus-associated cancer. Nature 1998; 393(6682): 229-31.
  10. Zehbe I, Voglino G, Wilander E, Genta F, Tommasino M. Codon 72 polymorphism of p53  and its association with cervical cancer. Lancet 1999; 354(9174): 218-9.
  11. Agorastos T, Lambropoulos AF, Constantinidis TC, Kotsis A, Bontis JN. p53 codon 72 polymorphism and risk of intra-epithelial and invasive cervical neoplasia in Greek women. Eur J Cancer Prev 2000; 9(2): 113-8.
  12. Helland A, Langerod A, Johnsen H, Olsen AO, Skovlund E, Borresen-Dale AL. p53  polymorphism and risk of cervical cancer. Nature 1998; 396(6711): 530-1.
  13. Josefsson AM, Magnusson PK, Ylitalo N, Quarforth-Tubbin P, Ponten J, Adami HO, et al. p53  polymorphism and risk of cervical cancer.
    Nature 1998; 396(6711): 531.
  14. Lanham S, Campbell I, Watt P, Gornall R. p53  polymorphism and risk of cervical cancer. Lancet 1998; 352(9140): 1631.
  15. Makni H, Franco EL, Kaiano J, Villa LL, Labrecque S, Dudley R, et al. P53 polymorphism in codon 72 and risk of human papillomavirus-induced cervical cancer: effect of inter-laboratory variation. Int J Cancer 2000; 87(4): 528-33.
  16. Soulitzis N, Sourvinos G, Dokianakis DN, Spandidos DA. p53 codon 72 polymorphism and its association with bladder cancer. Cancer Lett 2002; 179(2): 175-83.
  17. Zhang ZW, Newcomb P, Hollowood A, Feakins R, Moorghen M, Storey A, et al. Age-associated increase of codon 72 Arginine p53 frequency in gastric cardia and non-cardia adenocarcinoma. Clin Cancer Res 2003; 9(6): 2151-6.
  18. Dunning AM, Healey CS, Pharoah PD, Teare MD, Ponder BA, Easton DF. A systematic review of genetic polymorphisms and breast cancer risk. Cancer Epidemiol Biomarkers Prev 1999; 8(10): 843-54.
  19. Marin MC, Jost CA, Brooks LA, Irwin MS, O'Nions J, Tidy JA, et al. A common polymorphism acts as an intragenic modifier of mutant p53 behavior. Nat Genet 2000; 25(1): 47-54.
  20. Siddique MM, Balram C, Fiszer-Maliszewska L, Aggarwal A, Tan A, Tan P, et al. Evidence for selective expression of the pP53 codon 72 polymorphs: implications in cancer development. Cancer Epidemiol Biomarkers Prev 2005; 14(9): 2245-52.
 
  1. Muller PA, Vousden KH. Mutant p53 in cancer: new functions and therapeutic opportunities. Cancer Cell 2014; 25(3): 304-17
  2. Muller PA, Vousden KH. p53 mutations in cancer. Nat Cell Biol 2013; 15(1): 2-8.
  3. Dunna NR, Vure S, Sailaja K, Surekha D, Raghunadharao D, Rajappa S, et al. TP53  codon 72 polymorphism and risk of acute leukemia. Asian Pac J Cancer Prev 2012; 13(1): 347-50.
  4. Beckman G, Birgander R, Själander A, Saha N, Holmberg PA, Kivelä A, et al. Is p53 polymorphism maintained by natural selection? Hum Hered 1994; 44(5): 266-70.
  5. Ojeda JM, Ampuero S, Rojas P, Prado R, Allende JE, Barton SA, et al. p53 codon 72 polymorphism and risk of cervical cancer. Biol Res 2003; 36(2): 279-83.
  6. Zhu ZZ, Cong WM, Liu SF, Dong H, Zhu GS, Wu MC. Homozygosity for Pro of p53 Arg72Pro as a potential risk factor for hepatocellular carcinoma in Chinese population. World J Gastroenterol 2005; 11(2): 289-92.
  7. Lu XM, Zhang YM, Lin RY, Liang XH, Zhang YL, Wang X, et al. p53 polymorphism in human papillomavirus-associated Kazakh’s esophageal cancer in Xinjiang, China. World J Gastroenterol 2004; 10(19): 2775-8.
 
 
 
 
 
 
 

 
 
 
 
Sci J Iran Blood Transfus Organ 2015; 12(1): 23-31
 
Original  Article
 
 

Investigation of p53 codon 72 polymorphism in patients
 with acute myeloid leukemia in Iran
 
Nikbakht Dastjerdi M.1
 
 
1School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
 
 
 
Abstract
Background and Objectives
A common polymorphism at codon 72 in the p53 gene has been associated with the increased risk for lung, oral, prostate, breast and colorectal cancers. We studied this polymorphism in acute myeloid leukemia specimen from Alzahra Hospital in Isfahan city.
 
Materials and Methods
In the present case-control study, 59 whole blood specimen from normal people and 59 acutemyeloid leukemia specimen were analyzed. p53  codon 72  genotypes  were  identified   using   allele-specificPCR. Chi-square test was used for the comparison of the frequency distribution of three genotypes of codon 72 in cases and control specimen.
 
Results
Resulting PCR products were either 177bp for proline allele or 141bp for arginine allele. The genotype distribution for p53  polymorphism showed 11.9%, 81.4%, and 6.8% for the Arg/Arg, Arg/Pro, and Pro/Pro genotypes in control samples and 33.9%, 61%, and 5.1% in acute myeloid leukemia specimen, respectively.  The differences in the distribution of p53 codon 72 polymorphism between the cases and controls were statistically significant (p = 0.04).
 
Conclusions
Deferasirox is relatively more effective than deferoxamine in reducing iron content of the liver and heart. Moreover, deferasirox is more effective in reducing cardiac iron content relative to liver iron content.
 
Key words: TP53 Genes, Acute Myeloid Leukemia, Polymorphism(Genetic), Iran
 
 
 
 
 
 
 
 
 
Received: 22 Apr 2014
Accepted: 24 Sep 2014
 
 

 

Correspondence: Nikbakht Dastjerdi M., PhD of Anatomy. Associate Professor of School of Medicine, Isfahan University of Medical Sciences.
Postal Code: 81744176, Isfahan, Iran. Tel: (+98311) 37922403; Fax: (+98311) 37922517
E-mail: nikbakht@med.mui.ac.ir
Send email to the article author

Add your comments about this article
Your username or Email:

CAPTCHA


XML   Persian Abstract   Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Nikbakht Dastjerdi M. Investigation of p53 codon 72 polymorphism in patients with acute myeloid leukemia in Iran. Sci J Iran Blood Transfus Organ 2015; 12 (1) :23-13
URL: http://bloodjournal.ir/article-1-860-en.html


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 12, Issue 1 (Spring 2015) Back to browse issues page
فصلنامه پژوهشی خون Scientific Journal of Iran Blood Transfus Organ
The Scientific Journal of Iranian Blood Transfusion Organization - Copyright 2006 by IBTO
Persian site map - English site map - Created in 0.06 seconds with 39 queries by YEKTAWEB 4645